×

Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study

Published Sep 17 2021 at 10:05 PM GMT
Key
Points
  • Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study.




Trending

Stats

  • Published Sep 17, 2021 10:05 PM GMT